Evidence map›Paper›PMID 41882311›Full record

ReviewDiscover oncology2026

Regulatory role of IL-17-mediated inflammatory pathways in lung cancer initiation and progression.

Xinjia Xu, Xinan Lu, Wei Wu, Xinyi Chen, Aijun Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xinjia XuRespiratory and Critical Care Medicine, Cixi People's Hospital, Wenzhou Medical University, Ningbo, China.
Xinan LuRespiratory and Critical Care Medicine, Cixi People's Hospital, Wenzhou Medical University, Ningbo, China.
Wei WuRespiratory and Critical Care Medicine, Cixi People's Hospital, Wenzhou Medical University, Ningbo, China.
Xinyi ChenRespiratory and Critical Care Medicine, Cixi People's Hospital, Wenzhou Medical University, Ningbo, China.
Aijun ZhangRespiratory and Critical Care Medicine, Cixi People's Hospital, Wenzhou Medical University, Ningbo, China. nbzaj@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer continues to present a substantial global health and economic challenge, with consistently high rates of incidence and mortality. While there have been significant strides in precision diagnostics and treatment methods that have contributed to a reduction in mortality over previous years, progress has plateaued recently, largely due to complications such as side effects and resistance to therapies. Emerging research indicates that interleukin-17 (IL-17), a cytokine with pro-inflammatory properties, plays a critical role in various stages of lung cancer, including initiation, growth, invasion, metastasis, angiogenesis, lymphangiogenesis, and treatment resistance. This positions IL-17 as both a crucial regulator and a valuable prognostic marker for the disease's progression. This review aims to provide an overview of the most recent developments in IL-17 research as it relates to lung cancer, offering a theoretical framework for its potential as a therapeutic target in both the prevention and treatment of lung cancer.

Indexed as

CytokinesImmune checkpoint inhibitorsInflammationInterleukin-17Lung cancerTargeted therapy

Identifiers

PMID41882311
PMCPMC13139551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.